New breast imaging could make biopsies more accurate

NCT ID NCT06058650

Recruiting now Diagnosis Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether molecular breast imaging (MBI) can guide biopsies for breast abnormalities that are hard to see on ultrasound or mammography. About 70 women with a prior MBI finding that turned out to be benign will undergo a new MBI-guided biopsy procedure. The goal is to see if MBI can accurately target the lesion and improve biopsy success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Technetium Tc-99m Sestamibi
What this could lead to: If successful, this could make breast biopsies more accurate for lesions that are hard to see on standard imaging, potentially reducing missed cancers.
What could go wrong: This is a small pilot study (70 people) focused on workflow and accuracy, not on patient outcomes. The technique may not prove better than current methods or may be too slow for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASM

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.